FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca

March 20, 2024 – FACIT’s portfolio company Fusion Pharmaceuticals is being acquired by AstraZeneca for a total transaction value of up to $2.4 billion. Congratulations to the team at Fusion for building value over the last decade that will have a lasting impact on patients with cancer and the Ontario economy.

Read More from FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca

FACIT portfolio company Tenomix secures an all-Canadian investment round for colorectal cancer diagnostic

March 1, 2024 – FACIT congratulates London, Ontario based Tenomix Inc. (“Tenomix”) on successfully reaching a key milestone in closing its latest financing round to help propel the medtech start-up. Tenomix’s bench-top device will save time and costs by automating the process of lymph node identification in resected tissue while providing more accurate cancer staging for better patient care.

Read More from FACIT portfolio company Tenomix secures an all-Canadian investment round for colorectal cancer diagnostic

FACIT generates $1.5 billion in follow-on investment

March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.

Read More from FACIT generates $1.5 billion in follow-on investment

CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.

Read More from CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer